GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has expanded the eligible population for Arexvy, to include adults aged 18 to 49 years at increased risk for RSV disease. GSK’s RSV vaccine was previously approved in Japan for the prevention of RSV disease in all adults aged 60 years and older, and for adults aged 50-59 AIR for RSV disease. The prescribing information for Arexvy has also been updated to explicitly include immuno-compromised, IC, patients as an increased risk group – helping clinicians to identify people who may benefit from RSV prevention.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Davis to become acting director of CDER after Hoeg exit, Bloomberg says
- AnaptysBio price target raised to $90 from $85 at Leerink
- GSK’s B-Well 2 Hepatitis B Trial Reaches Completion, Setting the Stage for Key Data
- Trump Trade: Nvidia CEO joins China trip, Diamantas tapped as acting FDA chief
- Global Stocks, American Dollars: How ADRhedged™ ETFs Are Fixing the Most Overlooked Risk in International Investing